Switch theme
Sign up to access all valuation multiples
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
2010
353
LTM Revenue $52.8M
LTM EBITDA -$379M
-$37.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sage Therapeutics has a last 12-month revenue of $52.8M and a last 12-month EBITDA of -$379M.
In the most recent fiscal year, Sage Therapeutics achieved revenue of $41.2M and an EBITDA of -$409M.
Sage Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sage Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $86.5M | $41.2M | XXX | XXX | XXX |
| Gross Profit | $6.9M | $84.3M | XXX | XXX | XXX |
| Gross Margin | 8% | 204% | XXX | XXX | XXX |
| EBITDA | -$545M | -$409M | XXX | XXX | XXX |
| EBITDA Margin | -630% | -993% | XXX | XXX | XXX |
| Net Profit | -$533M | -$541M | XXX | XXX | XXX |
| Net Margin | -616% | -1313% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Sage Therapeutics's stock price is $7.
Sage Therapeutics has current market cap of $455M, and EV of -$37.6M.
See Sage Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$37.6M | $455M | XXX | XXX | XXX | XXX | $-5.70 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Sage Therapeutics has market cap of $455M and EV of -$37.6M.
Sage Therapeutics's trades at -0.7x LTM EV/Revenue multiple, and 0.1x LTM EBITDA.
Analysts estimate Sage Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Sage Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$37.6M | XXX | XXX | XXX |
| EV/Revenue | -0.9x | XXX | XXX | XXX |
| EV/EBITDA | 0.1x | XXX | XXX | XXX |
| P/E | -1.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSage Therapeutics's NTM/LTM revenue growth is 86%
Sage Therapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.3M for the same period.
Over next 12 months, Sage Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Sage Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Sage Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -52% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -993% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -25% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -907% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 525% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 548% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 1072% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sage Therapeutics acquired XXX companies to date.
Last acquisition by Sage Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Sage Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Sage Therapeutics founded? | Sage Therapeutics was founded in 2010. |
| Where is Sage Therapeutics headquartered? | Sage Therapeutics is headquartered in United States of America. |
| How many employees does Sage Therapeutics have? | As of today, Sage Therapeutics has 353 employees. |
| Who is the CEO of Sage Therapeutics? | Sage Therapeutics's CEO is Mr. Barry E. Greene. |
| Is Sage Therapeutics publicy listed? | Yes, Sage Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Sage Therapeutics? | Sage Therapeutics trades under SAGE ticker. |
| When did Sage Therapeutics go public? | Sage Therapeutics went public in 2014. |
| Who are competitors of Sage Therapeutics? | Similar companies to Sage Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Sage Therapeutics? | Sage Therapeutics's current market cap is $455M |
| What is the current revenue of Sage Therapeutics? | Sage Therapeutics's last 12-month revenue is $52.8M. |
| What is the current EBITDA of Sage Therapeutics? | Sage Therapeutics's last 12-month EBITDA is -$379M. |
| What is the current EV/Revenue multiple of Sage Therapeutics? | Current revenue multiple of Sage Therapeutics is -0.7x. |
| What is the current EV/EBITDA multiple of Sage Therapeutics? | Current EBITDA multiple of Sage Therapeutics is 0.1x. |
| What is the current revenue growth of Sage Therapeutics? | Sage Therapeutics revenue growth between 2023 and 2024 was -52%. |
| Is Sage Therapeutics profitable? | Yes, Sage Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
